Analysed EISAI CO LTD (ESAIY:OTCMKTS) News Sources
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
13-07-2026
yahoo.com
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
14-07-2026
yahoo.com
How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval
14-07-2026
yahoo.com
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
14-07-2026
yahoo.com
Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease
16-07-2026
yahoo.com
CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs
28-07-2026
yahoo.com
Eisai and CORE Biomedicine agree on global licence for oncology pipeline
29-07-2026
hospitalmanagement.net
What is the current price of EISAI CO LTD (ESAIY:OTCMKTS)?
The current price of EISAI CO LTD (ESAIY:OTCMKTS) is $7.46.
EISAI CO LTD (ESAIY:OTCMKTS) absolute price change since previous trading day?
The absolute price change of EISAI CO LTD (ESAIY:OTCMKTS) since the previous trading day is $-0.39.
EISAI CO LTD (ESAIY:OTCMKTS) percentage price change since previous trading day?
The percentage price change of EISAI CO LTD (ESAIY:OTCMKTS) since the previous trading day is -4.9682%.
What is the most recent average sentiment score for EISAI CO LTD (ESAIY:OTCMKTS)?
The most recent average sentiment score for EISAI CO LTD (ESAIY:OTCMKTS) is 72 out of 100.
What is the most recent average sentiment for EISAI CO LTD (ESAIY:OTCMKTS)?
The most recent sentiment for EISAI CO LTD (ESAIY:OTCMKTS) is .
SEC-8K** Filing Available For EISAI CO LTD (ESAIY:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.